Clinical Trials Browser

Phase 1/2 × Unknown × Lymphoma, B-Cell × Clear all

NCT04715217 2023-12-29

Targeting CD19 and CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory B Cell Lymphoma

Phase 1/2 Unknown

Lymphoma, B-Cell

NCT05932173 2023-07-11

A Study of Novel Anti-CD19 CAR-T in Patients With r/r B-Cell Malignancies

Phase 1/2 Unknown

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Leukemia, B-Cell, Lymphoma, B-Cell

NCT05771883 2023-05-24

A Clinical Study of Injectable IMM0306 in Combination With Lenalidomide

Phase 1/2 Unknown

Lymphoma, B-Cell

NCT04271410 2023-04-18

CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma

Phase 1/2 Unknown

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT04648475 2023-04-18

Safety and Efficacy of CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma

Phase 1/2 Unknown

LymphoidOther hematologic neoplasm

Leukemia, B-Cell, Lymphoma, B-Cell

NCT04649983 2023-04-18

CD19 and CD22 Targeted CAR-T Cell Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma

Phase 1/2 Unknown

LymphoidOther hematologic neoplasm

Leukemia, B-Cell, Lymphoma, B-Cell

NCT04782193 2023-04-18

a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B Cell Lymphoma

Phase 1/2 Unknown

Lymphoma, B-Cell

NCT05776407 2023-03-20

Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With Refractory or Relapsed B Cell Lymphoma

Phase 1/2 Unknown

Lymphoma, B-Cell

NCT05651100 2022-12-14

Safety and Efficacy of Sequential CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma

Phase 1/2 Unknown

Lymphoma, Lymphoma, B-Cell

NCT02481310 2022-02-21

Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma

Phase 1/2 Unknown

38 enrolled 12 charts

Plasmablastic Lymphoma, Burkitt Lymphoma, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT04747093 2021-02-10

Induced-T Cell Like NK Cells for B Cell Malignancies

Phase 1/2 Unknown

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, B-Cell, Lymphoma, B-Cell

NCT03265106 2021-02-04

A Clinical Study Evaluating the Safety and Efficacy of BinD19 Treatment in Childhood R/R ALL and Lymphoma Subjects

Phase 1/2 Unknown

Burkitt Lymphoma, Recurrence, Lymphoma, B-Cell

NCT04723914 2021-01-26

CAR-T

Phase 1/2 Unknown

Lymphoma, Recurrence, Lymphoma, B-Cell

NCT04429438 2020-06-12

Multi-CAR-T Cells Targeting B Cell Lymphomas

Phase 1/2 Unknown

Lymphoma, B-Cell

NCT02965092 2019-05-10

CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies

Phase 1/2 Unknown

LymphoidOther hematologic neoplasm

Lymphoma, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03366350 2019-05-10

Anti-CD19 CAR-T Therapy Bridging to HSCT for CD19+ B-Cell Malignancies

Phase 1/2 Unknown

LymphoidOther hematologic neoplasm

Lymphoma, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03366324 2018-11-20

Anti-CD19 CAR-T Therapy Combine With HSCT to Treat MRD+ B-cell Malignancies

Phase 1/2 Unknown

LymphoidOther hematologic neoplasm

Lymphoma, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03398967 2018-01-16

A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy for Relapsed or Refractory Leukemia and Lymphoma

Phase 1/2 Unknown

LymphoidOther hematologic neoplasm

Leukemia, B-Cell, Lymphoma, B-Cell

NCT02981745 2017-07-19

Study of Safety,Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia

Phase 1/2 Unknown

LymphoidOther hematologic neoplasm

Waldenstrom Macroglobulinemia, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT03166878 2017-06-23

A Study Evaluating UCART019 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma

Phase 1/2 Unknown

LymphoidOther hematologic neoplasm

Leukemia, B-Cell, Lymphoma, B-Cell

NCT03146533 2017-05-17

CD19 CART Cells for Patients With Relapse and Refractory CD19+ B-cell Lymphoma.

Phase 1/2 Unknown

Lymphoma, B-Cell

NCT02963038 2017-04-28

CAR T Cells for Refractory B Cell Malignancy

Phase 1/2 Unknown

LymphoidOther hematologic neoplasm

Leukemia, B-Cell, Lymphoma, B-Cell

NCT02965157 2016-11-16

Pilot Study of Anti-CD20-CAR-engineered T Cells in Patients With Chemotherapy Resistant or Refractory CD20+ Lymphoma

Phase 1/2 Unknown

Lymphoma, B-Cell

NCT01799083 2016-01-28

CIK

Phase 1/2 Unknown

Lymphoma, B-Cell

NCT02134262 2014-11-06

Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T Lymphocytes

Phase 1/2 Unknown

Burkitt Lymphoma, Immune System Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphomatoid Granulomatosis, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Experimental, Recurrence, Lymphoma, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Lymphoma, Extranodal NK-T-Cell

NCT02247609 2014-10-20

4SCAR19273

Phase 1/2 Unknown

Burkitt Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

NCT01435720 2014-09-11

Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL)

Phase 1/2 Unknown

LymphoidOther hematologic neoplasmPlasma cell

Blood Protein Disorders, Hematologic Diseases, Leukemia, Plasma Cell, Multiple Myeloma, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell, Neoplasms, Plasma Cell